Aileron Therapeutics, INC 8-K filings

Aileron Therapeutics has announced the resignation of its interim CFO and the appointment of a new CFO who will serve a short term before also departing.

Aileron Therapeutics has appointed Brian Windsor as its new CEO, succeeding Manuel Alves-Aivado, effective March 11, 2024.

Aileron Therapeutics announces the resignation of a board member and confirms it has regained compliance with Nasdaq listing rules regarding annual meetings.

Aileron Therapeutics' stockholders approved an increase in authorized shares and an amendment to the stock incentive plan at their 2023 annual meeting.

Aileron Therapeutics has awarded a $204,375 performance-based cash bonus to its Chief Operating Officer, Brian Windsor, Ph.D., requiring an update to the company's proxy statement.

Aileron Therapeutics has announced the date for its 2023 annual meeting of stockholders and deadlines for shareholder proposals and director nominations.

Aileron Therapeutics provides an update on its clinical programs for LTI-03 and LTI-01, along with details on the integration of Lung Therapeutics following its acquisition.

Aileron Therapeutics has finalized its acquisition of Lung Therapeutics, incorporating Lung's assets and pipeline into its operations.